Healthcare platform provider Transcarent, situated in San Francisco, California, has secured $126 million in Series D investment.
Investors
- General Catalyst
- 7wireVentures
- Memorial Hermann Health System and Geodesic Capital
- Threshold Ventures
- Kinnevik
- Ally Bridge Group
- Human Capital
- Merck Global Health Innovation Fund
- Alta Partners
- Leaps by Bayer
The money will be used by the firm to promote commercial expansion, strategic growth prospects, and the acceleration of AI capabilities.
Transcarent has expanded its value-based Surgery Centers of Excellence program and included complete Weight Health, Cancer, Behavioral Health, and Pharmacy Care Experiences since the Series C financing in January 2022.
The 98point6 AI-powered virtual care platform and care business, which includes the related Transcarent Clinic, were acquired and integrated by the corporation in 2023.
Transcarent also introduced the National Independent Provider Ecosystem, a collaboration with twelve health systems, to provide self-insured enterprises with a superior customer experience at a lower cost.
About Transcarent
Transcarent is a health and care platform that makes it simple for consumers to get care and for companies to offer and pay for that treatment. It is led by Glen Tullman, the chief executive officer, and Ken Frazier, the executive chairman. Through the solution, members may access a wide range of comprehensive care experiences, such as pharmacy care, surgery care (from the nation’s top hospitals, ambulatory care centers, and Centers of Excellence), weight health, and comprehensive cancer treatment. Everyday care also includes Care in 60 Seconds.
